Parathyroid hormone (PTH) was first used in the treatment of osteoporosis in 1929 when Fuller Albright demonstrated an increase in skeletal calcium in rats by injecting parathyroid extracts (1). This was later confirmed by Hans Selye in 1932 (2). The amino acid sequencing of PTH was performed in the early 1970s (3). Subsequently, small clinical studies were initiated to determine if PTH had therapeutic potential to augment bone mass in osteoporotic patients (4). Since then, a lot has been learned about the role of the amino terminal fragments of PTH in the treatment and prevention of osteoporosis in animals and humans. This article reviews the available evidence for the use of PTH fragments in osteoporosis, particularly glucocorticold-induced osteoporosis (GIOP).
|Original language||English (US)|
|Journal||Clinical and Experimental Rheumatology|
|Issue number||5 SUPPL. 21|
|State||Published - 2000|
- Glucocorticoid-induced osteoporosis
- Human parathyroid hormone (hPTH) (1-34)
ASJC Scopus subject areas